Evidence map›Paper›PMID 34835157›Full record

ArticleVaccines2021

Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT.

Markéta Šťastná-Marková, Eva Hamšíková, Petr Hainz, Petr Hubáček, Marie Kroutilová, Jitka Kryštofová, Viera Ludvíková, Jan Musil, Pavla Pecherková, Martina Saláková and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Markéta Šťastná-MarkováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Eva HamšíkováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Petr HainzInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Petr HubáčekLaboratory of Virology, Motol Hospital, 150 06 Prague, Czech Republic.
Marie KroutilováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Jitka KryštofováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Viera LudvíkováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Jan MusilInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Pavla PecherkováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Martina SalákováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Vojtěch ŠrollerInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Jan VydraInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Šárka NěmečkováInstitute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic.ORCID 0000-0001-6001-4007
Institute of Haematology and Blood Transfusion · CZCharles University · CZUniversity Hospital in Motol · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st-2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with "non-reactive" anti-BKPyV IgG levels and with low clinical risk (LCR) (

Indexed as

anti/BKPyV IgGhaemorrhagic cystitishemopoietic stem cell transplantationhuman BK polyomavirus 1 and 4 (BKPyV 1 and 4)immunocompromised patientsLTagT-cell responseVP1

Identifiers

PMID34835157
PMCPMC8625163
OpenAlexW3210148005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.